ESR1 and breast carcinoma: Herein, we demonstrate a role for ER in such feedback activation of survival pathways in breast cancer cell lines and human tumors, providing supportive rationale for using anti-estrogens to enhance the effects of mTORC1 inhibitors in ER+ breast cancer.